HRTXのチャート
HRTXの企業情報
| symbol | HRTx |
|---|---|
| 会社名 | Heron Therapeutics Inc （ヘロン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ヘロン・セラピューティクス(Heron Therapeutics Inc.)は癌と痛みに苦しむ患者のための医薬品の開発に従事するバイオテクノロジー企業。同社の薬品候補には、「SUSTOL」、「HTX-019」、「HTX-011」が含まれる。薬品候補のすべては、Biochronomer薬物送達技術を含む科学技術プラットフォームを利用する。中等度催吐性リスク化学療法(MEC)または高度催吐性化学療法(HEC)に関連する急性と遅延の化学療法誘発性悪心・嘔吐(CINV)の予防のために、同社はSUSTOL（グラニセトロン）徐放性注射剤を開発する。HTX-019は、ニューロキニン1(NK1)受容体アンタゴニストであるアプレピタントの静脈内製剤であり、CINVの予防のために開発される。HTX-011は、抗炎症性メロキシカムとの一定用量の組み合わせにおける局所麻酔薬ブピバカインの長期作用性製剤であり、術後疼痛の予防のために開発される。HTX-011は第2相臨床試験中である。 ヘロン・セラピュ―ティクスは米国の製薬会社。同社の独自技術のポリマ―ベ―スの薬物送達プラットフォ―ムBiochromerを使用して製品を開発する。主力製品のグラニセトロン注射「SUSTOL」は、急性遅延発症化学療法に伴う悪心・嘔吐の予防薬で、これは医薬品の活性成分の作用持続時間を延長することで効果を見込む。 Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. |
| 本社所在地 | 4242 Campus Point Court Suite 200 San Diego CA 92121 USA |
| 代表者氏名 | Kevin C. Tang ケヴィン・C・タング |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-366-2626 |
| 設立年月日 | 30348 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 145人 |
| url | www.appharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/hrtx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -192.54600 |
| 終値（lastsale） | 31 |
| 時価総額（marketcap） | 2409762804 |
| 時価総額 | 時価総額（百万ドル） 2264.4 |
| 売上高 | 売上高（百万ドル） 47.46900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1870.548 |
| 当期純利益 | 当期純利益（百万ドル） -195.29100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Heron Therapeutics Inc revenues increased from $12.1M to $28.8M. Net loss decreased 2% to $90.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 7% to $4.6M (expense) Stock-based Compensation in SGA decrease of 6% to $4.8M (expense). |
HRTXのテクニカル分析
HRTXのニュース
Heron Therapeutics PT Lowered to $5.50 at Cowen 2022/08/09 20:03:02 Investing.com
https://www.investing.com/news/pro/heron-therapeutics-pt-lowered-to-550-at-cowen-432SI-2868255
Heron Shares Jump After Equity Financing, Q2 Earnings 2022/08/09 18:10:16 Benzinga
Heron Therapeutics Inc (NASDAQ: HRTX ) reported Q2 sales of $27.63 million , +23.1% Y/Y, beating the consensus of $24.31 million. Oncology sales reached $25.1 million, up from $22.4 million a year ago. The company reported an EPS loss of $(0.55), narrower from $(0.62) a year ago but missing the consensus of $(0.50). In June … Full story available on Benzinga.com
Heron Therapeutics, Inc.''s (HRTX) CEO Barry Quart on Q2 2022 Results - Earnings Call Transcript 2022/08/09 18:05:05 Seeking Alpha
Heron Therapeutics, Inc. (NASDAQ:NASDAQ:HRTX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants David Szekeres – Executive Vice President, Chief Operating…
Heron Therapeutics PT Lowered to $30 at Evercore ISI 2022/08/09 15:27:01 Investing.com
https://www.investing.com/news/pro/heron-therapeutics-pt-lowered-to-30-at-evercore-isi-432SI-2868115
Heron Therapeutics rises 16% on Q2 revenue beat, raises 2022 sales forecast (NASDAQ:HRTX) 2022/08/09 15:18:12 Seeking Alpha
Heron Therapeutics (HRTX) is trading 16% higher after it reported better-than-expected Q2 revenue, helped by higher sales of postoperative pain drug Zynrelef. The company also…
Investment - Heron Therapeutics, Inc. Expected to Post Quarterly Sales of $24.68 Million 2022/05/29 07:27:08 Business Mag
Equities research analysts expect that Heron Therapeutics, Inc. will report sales of $24.68 million for the current fiscal quarter, Zacks Investment Research reports. Two…
What Could Change After Heron Therapeutics Inc. (NASDAQ: HRTX) Gains 3.14% From The High-Point? 2022/05/27 12:00:00 Marketing Sentinel
Heron Therapeutics Inc. (NASDAQ:HRTX)’s traded shares stood at 3.33 million during the last session, with the company’s beta value hitting 1.42. At the close of trading, the stock’s price was $3.18, to imply an increase of 2.58% or $0.08 in intraday trading. The HRTX share’s 52-week high remains $16.63, putting it -422.96% down since that … What Could Change After Heron Therapeutics Inc. (NASDAQ: HRTX) Gains 3.14% From The High-Point? Read More »
Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference 2022/05/26 20:05:00 PR Newswire
SAN DIEGO, May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that company management…
Shares Of Heron Therapeutics Inc. (NASDAQ: HRTX) Could Show A Loss Of -1042.86% 2022/05/11 13:30:00 Marketing Sentinel
In the last trading session, 6.1 million shares of the Heron Therapeutics Inc. (NASDAQ:HRTX) were traded, and its beta was 1.37. Most recently the company’s share price was $3.50, and it changed around -$0.11 or -3.05% from the last close, which brings the market valuation of the company to $385.84M. HRTX currently trades at a … Shares Of Heron Therapeutics Inc. (NASDAQ: HRTX) Could Show A Loss Of -1042.86% Read More »
Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q1 2022 Results - Earnings Call Transcript 2022/05/09 23:56:05 Seeking Alpha
Heron Therapeutics, Inc. (NASDAQ:NASDAQ:HRTX) Q1 2022 Results Conference Call May 09, 2022 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John…
Heron Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/03/04 21:13:23 Seeking Alpha
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off. 2022/03/04 21:00:00 The Motley Fool
Here''s why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.
Heron Therapeutics: Changing Strategy After Disappointing Earnings 2022/03/03 01:46:00 Seeking Alpha
Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference | MarketScreener 2022/03/02 21:06:07 MarketScreener
SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to… | March 2, 2022
Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference 2022/03/02 21:05:00 PR Newswire
SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that…